Effective Third-Line Treatment for Colorectal Cancer
Author Information
Author(s): He Chunxia, Chi Jiaxin, Du Zhihua, Zhuang Zhenjie, Li Liuning
Primary Institution: Guangdong Provincial Hospital of Chinese Medicine, University of Guangzhou Traditional Chinese Medicine
Hypothesis
Can the SFS regimen provide durable responses in patients with MSS mCRC and BRAF V600E mutation?
Conclusion
The SFS regimen may offer a promising third-line treatment option for patients with BRAF V600E-mutated MSS mCRC, achieving sustained remission for over 3 years.
Supporting Evidence
- The patient achieved stable disease after 40 cycles of the SFS regimen.
- She has remained in sustained remission for over 3 years.
- The SFS regimen may be an attractive therapeutic strategy for patients with BRAF V600E-mutated MSS mCRC.
Takeaway
A young woman with advanced colon cancer got better after a special treatment that combined three medicines, and she has stayed healthy for more than three years.
Methodology
The patient received 40 cycles of the SFS regimen consisting of S-1, fruquintinib, and sintilimab after failing previous treatments.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 23-year-old female patient with MSS mCRC and BRAF V600E mutation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website